Home » GlycoGenesys Gets GCS-100 Patent to Treat Angiogenesis-Related Diseases
GlycoGenesys Gets GCS-100 Patent to Treat Angiogenesis-Related Diseases
The U.S. Patent and Trademark Office has issued a patent protecting the use of GlycoGenesys' drug candidate GCS-100 and other modified pectins to control angiogenesis (the process by which new blood vessels are formed) and to treat angiogenesis-dependent diseases.
Angiogenesis plays an important role in cancer where GCS-100 is currently being tested, as well as, macular degeneration, endometriosis and many other diseases which rely on the formation of new vasculature.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct